Company news
Marker Therapeutics, Inc. news in 2026
Marker Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer
October 19, 2026
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
March 17, 2026
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
January 26, 2026
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
January 5, 2026